Background
==========

Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus* (VRE) emerged in continental Asia following dissemination from Europe and North America \[[@B1]\]. Over the past decade these pathways have reversed, with Asia the probable source of broad-spectrum β-lactamases such as CTX-M-15 and NDM-1 \[[@B2],[@B3]\]. Both are now identified globally.

VRE is relatively uncommonly identified in Asia, while MRSA has become established in Asian hospitals and is emerging in the community \[[@B4]\]. Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) have reached an extraordinary prevalence in clinical isolates from both hospitals and the community. Surveillance by the Study for Monitoring Antimicrobial Trends (SMART) in the Asia-Pacific region from 2008--2010 detected ESBL-E in 32.8% of urinary tract infections and 11.2% of intra-abdominal infections (IAI) \[[@B5],[@B6]\]. Almost 20% of ESBL-E were cultured from community-onset IAI. ESBL-E fecal carriage rates among healthy volunteers in Asia have ranged from 6.4% in Japan to an extraordinary 61.7% in rural Thailand \[[@B7],[@B8]\].

As many bacterial infections derive from host flora, colonization by drug resistant organisms is a risk for drug resistant infections \[[@B9],[@B10]\]. An increased mortality with these infections correlates with delayed recognition and inadequate empirical therapy \[[@B11],[@B12]\]. Knowledge of local resistance patterns is therefore important for evidence-based institutional empiric antibiotic treatment and infection control guidelines. We developed a prospective study to determine the prevalence of colonization by ESBL-E, MRSA and VRE in patients admitted to our hospital in Singapore, and to explore some of the associated risk factors.

Methods
=======

Participants and setting
------------------------

We conducted this prospective observational study at the emergency department (ED) of Tan Tock Seng Hospital, Singapore. This is a public tertiary hospital of more than 1500 inpatient beds and a busy ED with more than 11,000 attendances and almost 4000 admissions per month in 2006.

Consecutive patients over 16 years of age planned for hospital admission were approached to participate. The recruitment period was 12-8 pm Monday to Friday from November 2006 to February 2007. Pregnant women were excluded. Target recruitment was 1000, calculated to estimate the colonization rate for MRSA with 95% confidence within 1% of its actual value, based on an expected value of 2% from previous institutional surveillance studies.

Anterior nares, groin, axilla and rectum were swabbed by a research nurse in the ED. If the participant declined or was unsuitable for rectal swabbing, freshly passed stools were collected within 24 hours of admission. Clinical data recorded at admission from the participant or next-of-kin included age, gender, co-morbidities, residence in a care facility, hospitalization or outpatient (hospital and primary care) healthcare contact within the last 12 months and receipt of antibiotics in the last 3 months.

Written informed consent was obtained from all participants or the next-of-kin and the study was approved by the Institutional Ethics Committee (the National Healthcare Group Domain Specific Review Board).

Bacteria identification and resistance testing
----------------------------------------------

Rectal swabs/stool specimens were inoculated onto two MacConkey agar plates supplemented with 1 mg/L of either cefotaxime or ceftazidime and incubated for 48 hours. Enterobacteriaceae were identified by Microbact 12A (Oxoid, UK) and the presence of ESBL screened with double-disc synergy using cefotaxime 30 μg and ceftazidime 30 μg discs placed 25 mm from an amoxicillin-clavulanate (20 μg-10 μg) disc. Isolates screening positive for ESBL were tested with a multiplex PCR assay for detection of CTX-M clusters, according to published protocols \[[@B13]\].

Nares, groin and axillary swabs were inoculated onto mannitol salt agar supplemented with oxacillin 6 μg/ml and incubated for 48 hours. MRSA was identified by gram stain, tube coagulase test and antimicrobial susceptibility testing.

Rectal swabs/stool specimens were also inoculated onto bile-esculin-azide agar containing 6 mgs/L vancomycin for 48 hours and black colonies identified as enterococci by conventional methods including motility and pigment production. Vancomycin resistance was confirmed using vancomycin minimum concentration (MIC) E-test (AB BioDisk, Sweden) and an in-house *van* gene polymerase chain reaction (PCR).

Disc diffusion anti-microbial susceptibility testing was performed for all isolates in accordance with the 2007 Clinical Laboratory Standard Institute Guidelines \[[@B14]\].

Data analysis
-------------

An initial exploratory analysis was performed with Fisher's exact test. Logistic regression was used to determine which covariates were significantly associated with the detection of ESBL-E, MRSA or VRE. All identified covariates were entered into the model before employing a backward elimination algorithm. Goodness-of-fit was estimated with the Hosmer Lemeshow (H-L) test. The sensitivity and specificity of individual measures for predicting colonization was estimated using the efficient-score method.

Participants who reported no contact with healthcare, healthcare workers, antibiotics or nursing homes were used as a surrogate for the community prevalence of colonization by ESBL-E, MRSA or VRE.

Statistical analyses were performed using Stata 12.0 (Stata Corporation, U.S.A.). All statistical tests were conducted at a two-sided 5% level of significance.

Results
=======

1006 out of 1592 patients (63.2%) admitted during the recruitment period consented to participate. Rectal swabs were obtained from 1001 (99.5%); 3 (0.3%) provided stool specimens; 2 (0.2%) did not provide any sample. MRSA screening was performed on all 1006.

Baseline characteristics and findings are summarized in Table  [1](#T1){ref-type="table"}. 124 (12.4%) were colonized by ESBL-E, 18 (1.8%) by MRSA, and no VRE was detected.

###### 

Sample characteristics and univariate analysis

                                 **MRSA No (n = 988)**   **Yes (n = 18)**   **p-value**   **ESBL-E No (n = 880)**   **Yes (n = 124)**   **p-value**
  ------------------------------ ----------------------- ------------------ ------------- ------------------------- ------------------- -------------
  **Demographics:**                                                                                                                     
  Gender                                                                                                                                 
   Male                          643 (98.2%)             12 (1.8%)          NS            571 (87.2%)               84 (12.8%)          NS
   Female                        345 (98.3%)             6 (1.7%)                         309 (88.5%)               40 (11.5%)           
  Ethnicity                                                                                                                              
   Chinese                       639 (97.6%)             16 (2.4%)          NS            571 (87.2%)               84 (12.8%)          NS
   Malay                         166 (99.4%)             1 (0.6%)                         149 (89.2%)               18 (10.8%)           
   Indian                        133 (99.2%)             1 (0.8%)                         115 (86.5%)               18 (13.5%)           
   Others                        50 (100.0%)             0 (0.0%)                         45 (91.8%)                4 (8.2%)             
  Residence in Nursing Home                                                                                                              
   No                            966 (98.2%)             18 (1.8%)          NS            860 (87.6%)               122 (12.4%)         NS
   Yes                           22 (100.0%)             0 (0.0%)                         20 (90.9%)                2 (9.1%)             
  **Comorbid conditions:**                                                                                                              
  Diabetes Mellitus                                                                                                                      
   No                            782 (98.7%)             10 (1.3%)          0.035         697 (88.2%)               93 (11.8%)          NS
   Yes                           206 (96.3%)             8 (3.7%)                         183 (85.5%)               31 (11.5%)           
  ESRF                                                                                                                                   
   No                            977 (98.2%)             18 (1.8%)          NS            869 (87.5%)               124 (12.5%)         NS
   Yes                           11 (100.0%)             0 (0.0%)                         11 (100.0%)               0 (0.0%)             
  Liver Cirrhosis                                                                                                                        
   No                            977 (98.2%)             18 (1.8%)          NS            869 (87.5%)               124 (12.5%)         NS
   Yes                           11 (100.0%)             0 (0.0%)                         11 (100.0%)               0 (0.0%)             
  Cancer                                                                                                                                 
   No                            962 (98.2%)             18 (1.8%)          NS            854 (87.3%)               124 (12.7%)         NS
   Yes                           26 (100.0%)             0 (100.0%)                       26 (100.0%)               0 (0.0%)             
  HIV                                                                                                                                    
   No                            985 (98.2%)             18 (1.8%)          NS            878 (87.7%)               123 (12.3%)         NS
   Yes                           3 (100.0%)              0 (0.0%)                         2 (66.7%)                 1 (33.3%)            
  Corticosteroids                                                                                                                        
   No                            944 (98.2%)             17 (1.8%)          NS            845 (88.1%)               114 (11.9%)         NS
   Yes                           43 (97.7%)              1 (2.3%)                         34 (77.3%)                10 (22.7%)           
  **Healthcare risk factors:**                                                                                                          
  Hospitalization                                                                                                                        
   Within 3 month                155 (93.4%)             11 (6.6%)          \<0.001       131 (78.9%)               35 (21.1%)          \<0.001
   Within 12 month               297 (95.5%)             14 (4.5%)          \<0.001       257 (82.6%)               54 (17.4%)          0.002
  Oral antibiotics                                                                                                                       
   Within 1 month                279 (97.2%)             8 (2.8%)           NS            227 (79.1%)               60 (20.9%)          \<0.001
   Within 3 month                343 (97.4%)             9 (2.6%)           NS            286 (81.3%)               66 (18.7%)          \<0.001
  Outpatient hospital visit                                                                                                              
   Within 3 month                402 (96.9%)             13 (3.1%)          0.013         347 (83.8%)               67 (16.2%)          0.002
   Within 12 month               536 (97.3%)             15 (2.7%)          0.016         470 (85.4%)               80 (14.6%)          0.021
  Primary care visit                                                                                                                     
   Within 3 month                657 (97.6%)             16 (2.4%)          0.046         584 (87.0%)               87 (13.0%)          NS
   Within 12 month               729 (97.9%)             16 (2.1%)          NS            652 (87.8%)               91 (12.2%)          NS
  HCW contact                                                                                                                            
   No                            853 (98.3%)             15 (1.7%)          NS            759 (87.5%)               108 (12.5%)         NS
   Yes                           135 (97.8%)             3 (2.2%)                         121 (88.3%)               16 (11.7%)           

ESRF: End-stage Renal Failure; HIV: Human Immunodeficiency Virus; HCW: Healthcare Worker.

Univariate analysis and logistic regression
-------------------------------------------

Inpatient or outpatient hospital care and recent antibiotic prescription were significant risk factors for ESBL-E colonization in the univariate analysis (Table  [1](#T1){ref-type="table"}). In the logit model only antibiotic use within 1 month prior to admission significantly predicted ESBL-E colonization, with an AOR of 2.58 \[1.04 to 6.42\] (Table  [2](#T2){ref-type="table"}).

###### 

Multiple logistic regression analyses of MRSA and ESBL-E colonization risk factors

  **Featured covariates\***         **MRSA AOR**    **95% C.I.**    **ESBL-E AOR**   **95% C.I.**
  -------------------------------- --------------- --------------- ---------------- --------------
  Hospitalization                                                                          
   Within 3 month                       3.81        0.84 to 17.28        1.38        0.71 to 2.69
   Within 12 month                      3.48        0.64 to 18.92        1.35        0.73 to 2.48
  Use of oral antibiotics                                                                  
   Within 1 month                       1.57        0.17 to 14.43      2.58\*\*      1.04 to 6.42
   Within 3 month                       0.67        0.08 to 6.78         0.94        0.38 to 2.36
  Outpatient visit                                                                         
   Within 3 month                       0.97        0.17 to 5.64         1.36        0.69 to 2.69
   Within 12 month                      1.43        0.18 to 11.13        0.89        0.43 to 1.80
  Primary care visit                                                                       
   Within 3 month                   Not estimated   Not estimated        2.08        0.72 to 6.01
   Within 12 month                  Not estimated   Not estimated        0.41        0.14 to 1.24
  Contact with Healthcare Worker        1.30        0.32 to 5.33         0.86        0.47 to 1.57

*\**The models are adjusted for demographics and co-morbid conditions.

\*\*Statistically significant at 5%.

For MRSA colonization, inpatient or outpatient hospital care within the previous 3 or 12 months were significantly associated in the univariate analysis (Table  [1](#T1){ref-type="table"}). Neither factor was statistically significant in the logit model. Adjusted odds ratios (AOR) for MRSA colonization following hospitalization in the past 3 and 12 months were 3.81 \[95% CI 0.84-17.28\] and 3.48 \[0.64-18.92\] respectively (Table  [2](#T2){ref-type="table"}).

Both logit models provided a satisfactory fit to the data (H-L test: ESBL-E p-value = 0.52, MRSA p-value = 0.87).

Community colonization
----------------------

95 participants reported no contact with healthcare, healthcare workers, antibiotics or nursing homes; 6 (6.3%) were colonized by ESBL-E, 0 by MRSA and 0 by VRE.

The importance of recent antibiotic use for ESBL-E colonization was evident from a comparison of colonization rates in participants stratified by attendance at different levels of the healthcare system in the previous three months, and antibiotic use in the previous month (Table  [3](#T3){ref-type="table"}). Baseline colonization prevalence in each subgroup was not significantly different from the putative community prevalence of 6.3% (Fisher's exact test), however prevalence was significantly higher than baseline if antibiotics were administered in the previous month. In participants who had been recently admitted to hospital and received antibiotics, 29.4% were colonized by ESBL-E.

###### 

ESBL-E fecal colonization by healthcare contact in the past three months and antibiotic use in the previous month

  **Sub-group**                           **Number of participants**   **Prevalence**   **Odds ratio (95% C.I.)**        **p-value**       
  -------------------------------------- ---------------------------- ---------------- --------------------------- ----------------------- ----------
  No healthcare contact or antibiotics                6                      95                   6.3%                                     
  Primary care, no antibiotics                        36                    452                   8.0%              2.90\* (1.84 to 4.57)   \<0.0001
  Primary care and antibiotics                        51                    221                   23.1%                                    
  Outpatient, no antibiotics                          24                    245                   9.8%              1.78\* (1.05 to 3.02)    0.033
  Outpatient and antibiotics                          43                    247                   17.4%                                    
  Hospitalization, no antibiotics                     10                     81                   12.3%             2.38\* (1.08 to 5.02)    0.032
  Hospitalization and antibiotics                     25                     85                   29.4%                                    

\*Statistically significant at 5%.

Predicting colonization
-----------------------

Oral antibiotics in the past month predicted ESBL-E fecal carriage with a sensitivity of 48.4% \[95% CI 39.4--57.5%\] and specificity of 74.2% \[71.2--77.0%\]. Specificity could be improved by filtering for additional hospitalization in the past 3 months, but with a significant loss of sensitivity: this was 22.1% \[15.3-28.2%\] sensitive and 89.4% \[87.0-91.3%\] specific. Specificity was improved further by combining oral antibiotics in the past month and hospitalization within the past 3 months. This predicted ESBL-E fecal carriage with 20.2% \[13.7--28.5%\] sensitivity and 93.2% \[91.3-94.7%\] specificity.

Hospitalization within the last 3 months was 61.1% \[95% CI 36.1-81.7%\] sensitive and 84% \[81.9-86.5%\] specific for MRSA colonization. Sensitivity could be improved to 77.8% \[51.9-92.6%\], but with a specificity of 69% \[70.0-72.8%\] using hospitalization in the past 12 months to predict MRSA colonization.

Extended spectrum β-lactamases
------------------------------

133 Enterobacteriaceae isolates from 124 participants tested positive for ESBL production by double disc synergy. 71% of these were *E.coli* and 19% *K.pneumoniae.* 99 (74.4%) were PCR positive for at least one CTX-M enzyme, predominantly cluster 1 (64 isolates, 65%) or 9 (32 isolates, 24%). 3 isolates produced both cluster 1 and 9 CTX-M.

Discussion
==========

Ceftriaxone resistance among clinical isolates of *E.coli* and *K.pneumoniae* from public hospitals in Singapore has reached 20-30% \[[@B15]\]. This incidence is rising and correlates with increasing prescription of broad spectrum antibiotics. We identified a similar high burden of ESBL-E colonization from rectal swab cultures. ESBL-E was detected in 29.4% of subjects who had been recently hospitalized and were recipients of antibiotics. 6.3% of subjects without healthcare contact or antibiotics were detected as ESBL-E colonized. The source of these organisms is of major concern.

In ESBL-E high prevalence countries such as Singapore, nosocomial transmission may not be the most important acquisition route. A study in a Swiss hospital with low ESBL-E prevalence observed infrequent transmission events even without contact isolation \[[@B16]\]. Modeling ESBL-E colonization in a French pediatric unit described the success of contact isolation in preventing nosocomial transmission, but its overall ineffectiveness due to the high incidence of sporadic cases from the community \[[@B17]\]. A similar finding from a study of ESBL-E transmission dynamics in Switzerland, detected more inpatient ESBL-E fecal carriage acquired from the community than in hospital \[[@B18]\]. Transmission between household members was also more frequent than between patients, though it was not clear if it was acquired from a common source -- presumed to be food -- or person-to-person.

The importance of recent antibiotic use in this study suggests that host susceptibility to colonization is a critical factor. Acquisition of ESBL-E from community or nosocomial sources may be facilitated by disrupting the host gut microbiome and providing a selective advantage for antibiotic-resistant organisms. Given the high rate of colonization in patients with no identified risk factors, an alternative hypothesis is that antibiotic use selects for ESBL-E from host indigenous gut flora, increasing the colonization burden. The sensitivity of rectal swabs for detection of ESBL-E has not been widely investigated, but was reported to correlate with density of colonization \[[@B19]\]. Antibiotics also generate *de novo* ESBL-E, by promoting DNA recombination events between gut bacteria \[[@B20]\].

Travel to Asia has been identified as a risk factor for ESBL-E fecal carriage in European and Australian prospective cohorts \[[@B21],[@B22]\]. In both these studies, acquisition was associated with traveler's diarrhea, but not dependent on antibiotic use or healthcare contact. Curiously this is despite the isolation of ESBL-E from more than 90% of retail chicken meat in separate European studies \[[@B23],[@B24]\]. This disconnect could be due to environmental or diet differences facilitating ESBL-E acquisition in Asia, or microbiome changes as a result of travel itself increasing susceptibility to colonization by antibiotic-resistant bacteria. CTX-M production by *E.coli* carried on chicken, pigs and cattle in China has been reported, and a systematic study of agricultural, food and clinical ESBL-E isolates in Asia would be interesting \[[@B25]\].

MRSA is a common healthcare-associated pathogen in Singapore. A colonization prevalence of 41% has been reported from nursing homes residents admitted to a public acute care hospital, and 6% among all medical and surgical admissions \[[@B26]\]. Community-acquired MRSA strains are infrequently recognized as a cause of infections in Singapore, and its contribution to community MRSA colonization is not known \[[@B27]\].

Transmission of MRSA from colonized hands and environmental surfaces to new hosts is well established \[[@B28],[@B29]\]. The high AOR in the logit model between hospitalization and MRSA colonization is consistent with this as a clinically significant factor. Antibiotic use has also been associated with colonization and infection by MRSA. Failure to identify this here may be due to the small number of cases \[[@B30],[@B31]\]. Failure to isolate VRE was not unexpected, as the prevalence in Singapore is low outside of nosocomial outbreaks \[[@B32]\].

This study has a number of limitations. Accurate clinical data was dependent on recall by study participants or next-of-kin and was not independently verified by medical records. Data was not collected on antibiotic type and duration or frequency of prior contact with healthcare institutions as this was judged unreliable from patient recall. Our ability to analyze risk factors for colonization by MRSA and VRE was limited by the study design, due to the low detected prevalence. A case control study would help elaborate these.

Acquisition rates in hospital were not investigated, and this could have provided additional evidence to refine our conclusions. More accurate methods for detecting MRSA, ESBL-E and VRE colonization are now available: for example PCR-based detection methods may be more accurate and sensitive \[[@B33]\]. We were also unable to perform ESBL genotyping or bacterial strain typing, to determine if CTX-M-15 was the major enzyme in clusters 1 and 9, or if ESBL-E strains differed between apparent community- and hospital-acquired isolates. The prevalence of resistance mechanisms such as carbapenemases which have become of increasing concern was not assessed.

Conclusions
===========

ESBL-E colonization was detected with high prevalence in subjects who were recently hospitalized and received antibiotics. Identifying subjects who were colonized by ESBL-E accurately was difficult using just the clinical data collected. Not least this was due to the significant proportion of ESBL-E associated with limited healthcare contact. Identifying the source of these organisms and the relative contributions of community and nosocomial transmission may be important for understanding how to control their spread.
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